Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.

Journal Article

PURPOSE: To determine if head and neck (H/N) cancer patients receiving daily amifostine during radiation therapy (RT) experienced clinical benefit (improvement in their ability to carry out normal functions with reduced discomfort) compared to nonamifostine treated patients. METHODS AND MATERIALS: This was an open-label, multi-institutional randomized trial in 303 H/N cancer patients treated with RT +amifostine. Clinical benefit was measured using an 8-item validated Patient Benefit Questionnaire (PBQ) during and up to 11 months after RT. RESULTS: 301 patients completed one or more PBQ assessments. Amifostine patients had significantly better PBQ scores (p < 0.05) than controls. The improvement in PBQ scores was most significant during chronic xerostomia. CONCLUSIONS: Amifostine use results in improved Patient Benefit Questionnaire (PBQ) scores, which is indicative of improved oral toxicity related outcomes and improved clinical benefit. Less oral toxicity should lead to preservation of late dental and oral health, and improvements in activities such as diet, nutrition, and sleep.

Full Text

Duke Authors

Cited Authors

  • Wasserman, T; Mackowiak, JI; Brizel, DM; Oster, W; Zhang, J; Peeples, PJ; Sauer, R

Published Date

  • November 1, 2000

Published In

Volume / Issue

  • 48 / 4

Start / End Page

  • 1035 - 1039

PubMed ID

  • 11072160

International Standard Serial Number (ISSN)

  • 0360-3016

Language

  • eng

Conference Location

  • United States